Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02950467 · ClinicalTrials.gov registry record · Phase 1

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

A Phase 1 study of Depression and Grief, sponsored by Joshua Woolley.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT02950467: Completed Phase 1 study of Depression and Grief, sponsored by Joshua Woolley.

NCT02950467 is a Phase 1 study of Depression and Grief that has completed, run by Joshua Woolley. The registered enrollment target is 30 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02950467, a Phase 1 study of Depression and Grief, has completed, sponsored by Joshua Woolley.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).

Primary Outcome

Full details of adverse event data are in the Adverse Events module of this ClinicalTrials.gov entry. Adverse events were assessed at every study visit by patient interview. During medication visits, adverse events were also assess by vitals sign monitoring, patient self-report, and adverse events observed by clinicians.

Interventions

  • DRUG Psilocybin
  • BEHAVIORAL Modified brief Supportive Expressive Group Therapy

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-01-05
Est. Completion 2019-12-31
Phase Phase 1
Joshua Woolley

1 total trials

What the finished NCT02950467 record still lists

NCT02950467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin is the first listed.

NCT02950467 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02950467 about?

NCT02950467 is a clinical study titled "Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors". The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).

What is the current status of trial NCT02950467?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-01-05. Estimated completion is 2019-12-31.

What conditions does trial NCT02950467 study?

This clinical trial studies the following conditions: Depression, Grief, Distress.

What interventions are being tested in trial NCT02950467?

The interventions under investigation include: Psilocybin (DRUG), Modified brief Supportive Expressive Group Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT02950467?

This trial is sponsored by Joshua Woolley, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02950467 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02950467's enrollment target sits among peer trials

30 557th of 679 higher than 105 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT02950467, the US trial registry maintained by the National Library of Medicine. NCT02950467 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.